Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Morphological Changes
100%
Hemodynamic Changes
100%
Angiotensin-converting Enzyme Inhibition
100%
Mitral Regurgitation
100%
Valvular Regurgitation
100%
Aortic Regurgitation
83%
Quinapril
66%
Angiotensin-converting Enzyme Inhibitor (ACEi)
50%
Left Ventricular Mass
33%
Left Ventricular Hypertrophy
33%
Mass Reduction
16%
Treatment Effect
16%
Moderate to Severe
16%
Preload
16%
Treatment Control
16%
Control Value
16%
Mitral Valve Repair
16%
During Exercise
16%
Left Ventricular Ejection Fraction
16%
Hypertrophy
16%
Afterload
16%
End-systolic Volume
16%
Coronary Disease
16%
Left Ventricular Dilation
16%
Left Ventricular End Diastolic
16%
Left Ventricular Function
16%
Echocardiographic
16%
Regurgitant Fraction
16%
Aortic Valve Replacement
16%
Myocardial Performance
16%
Acute Aortic Regurgitation
16%
Septal Wall Thickness
16%
Left Ventricular End-diastolic Volume (LVEDV)
16%
Medicine and Dentistry
Morphology
100%
Hemodynamic
100%
Dipeptidyl Carboxypeptidase
100%
Mitral Insufficiency
100%
Aortic Insufficiency
100%
Enzyme Inhibition
100%
Quinapril
66%
ACE Inhibitor
50%
Coronary Artery Disease
16%
Heart Preload
16%
Afterload
16%
Left Ventricular Hypertrophy
16%
End-Systolic Volume
16%
End-Diastolic Volume
16%
Heart Left Ventricle Ejection Fraction
16%
Mitral Valve Replacement
16%
Heart Left Ventricle Function
16%
Heart Performance
16%
Aortic Valve Replacement
16%
Regurgitant Fraction
16%
Pharmacology, Toxicology and Pharmaceutical Science
Enzyme Inhibition
100%
Dipeptidyl Carboxypeptidase
100%
Aortic Regurgitation
100%
Mitral Valve Regurgitation
100%
Quinapril
66%
Dipeptidyl Carboxypeptidase Inhibitor
50%
Coronary Artery Disease
16%
Heart Left Ventricle Hypertrophy
16%